Dianthus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-84.97	-43.56	-28.48	-13.11
Depreciation & Amortization	0.41	0.36	0.15	-
Loss (Gain) From Sale of Investments	-6.17	-1.42	-0.61	-
Stock-Based Compensation	12.89	2.9	1.52	0.06
Change in Accounts Receivable	0.18	0.75	0.07	-1.01
Change in Accounts Payable	8.19	0.66	2.28	4.92
Change in Unearned Revenue	1.55	-0.06	0.89	-
Change in Other Net Operating Assets	-10.28	3.5	-4.89	-0.77
Operating Cash Flow	-78.18	-36.86	-29.07	-9.9
Capital Expenditures	-0.11	-0.11	-0.14	-0.03
Investment in Securities	-286.71	20.36	-59.68	-
Investing Cash Flow	-286.81	20.25	-59.82	-0.03
Short-Term Debt Issued	-	0.38	-	-
Total Debt Issued	-	0.38	-	-
Short-Term Debt Repaid	-	-0.38	-	-
Total Debt Repaid	-	-0.38	-	-
Issuance of Common Stock	270.29	0.01	-	-
Other Financing Activities	-14.67	133.57	-3.32	-0.09
Financing Cash Flow	255.62	133.57	96.68	14.91
Net Cash Flow	-109.37	116.97	7.79	4.98
Free Cash Flow	-78.29	-36.97	-29.21	-9.94
Free Cash Flow Margin	-1255.57%	-1308.24%	-455.18%	-673.24%
Free Cash Flow Per Share	-2.35	-7.17	-33.41	-2.48
Levered Free Cash Flow	-43.48	-22.81	-19.31	-
Unlevered Free Cash Flow	-43.48	-22.81	-19.31	-
Change in Net Working Capital	-6.99	-4.15	2.27	-

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q